|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
PIK3CA, BRAF, KRAS and AKT1 mutations are very infrequent events in prostate tumors.
|
21113138 |
2011 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A mutational profiling of AKT1 and of the mutational hotspots in PIK3CA and PIK3R1 was carried out in samples from primary and recurrent prostate tumours.
|
20407443 |
2010 |
|
Prostatic Neoplasms
|
0.400 |
GeneticVariation
|
group |
LHGDN |
An activating mutation in AKT1 in human prostate cancer.
|
18798258 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Cholesterol level of lipid raft microdomains regulates apoptotic cell death in prostate cancer cells through EGFR-mediated Akt and ERK signal transduction.
|
17469127 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer.
|
17148458 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Attenuation of apoptosis by chromogranin A-induced Akt and survivin pathways in prostate cancer cells.
|
17584963 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract.
|
16820098 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells.
|
15467757 |
2004 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Combination of Pim and AKT inhibitors resulted in synergistic inhibition of prostate tumor growth in vitro and in vivo.
|
23585456 |
2013 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78.
|
16543232 |
2006 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here we identify the AKT-inactivating phosphatase PHLPP1 as a prostate tumor suppressor.
|
21840483 |
2011 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
DHA also inhibits AKT(T308) but not AKT(S473) phosphorylation, alters PI(3,4,5)P3 (PIP3) and phospho-AKT(S473) protein localization, decreases pPDPK1(S241)-AKT and AKT-BAD interaction and suppresses prostate tumor growth.
|
23633519 |
2013 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Increased phospho-AKT is associated with loss of the androgen receptor during the progression of N-methyl-N-nitrosourea-induced prostate carcinogenesis in rats.
|
15682402 |
2005 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3KAkt.
|
17898861 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Remnant lipoproteins stimulate proliferation and activate MAPK and Akt signaling pathways via G protein-coupled receptor in PC-3 prostate cancer cells.
|
17512923 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins.
|
18512729 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway.
|
18924134 |
2009 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.
|
19116269 |
2009 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival.
|
18776922 |
2008 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Array analyses of transcription in multiple murine prostate tumor models featuring PI3K/AKT pathway activation allowed construction of a pathway signature that may be useful in predicting the prognosis of human prostate tumors.
|
20534477 |
2010 |
|
Prostatic Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence.
|
15475446 |
2004 |
|
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation.
|
17606718 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms.
|
17823925 |
2007 |
|
Prostatic Neoplasms
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
|
16114056 |
2006 |